Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05060744
Other study ID # URI-AQUAA-2020-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 9, 2021
Est. completion date June 30, 2023

Study information

Verified date October 2022
Source Uriach Consumer Healthcare
Contact Anna Fortuny
Phone +34 938 630 311
Email anna.fortuny@uriach.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and Reduce Symptoms of Gastric Reflux and Hyperacidity.


Description:

The investigators will include patients with gastroesophageal reflux disease and heartburn (more than 3 weekly episodes of heartburn for at least 4 consecutive weeks) not related to medication intake and don't use proton pump blockers or H2-receptor antagonists. This is a multicentre clinical trial with two-phase design: Phase I: A double-blind, randomised, placebo-controlled clinical trial to assess the efficacy and rapidity of action of the medical device to reduce clinical symptoms of gastric reflux and hyperacidity under normal conditions of use. This phase I will be performed in primary care clinics. Phase II: A non-comparative, non-controlled clinical trial to objectively assess, using continuous pH monitoring, the magnitude and rapidity to control gastric and oesophageal pH after taking the product. This phase II will be performed at the Department of Gastroenterology of Medic Center. The study will begin with the baseline visit (day 0) in which the inclusion and exclusion criteria will be confirmed, the signing of informed consent will be obtained, GERD-Q Questionnaire will be done and treatment will be prescribed, followed by a home recording where patients will record data on episodes of acidity and heartburn occuring during the follow-up week. A face-to-face visit will be at 7 days after to recollect information about total number of daytime and nighttime episodes of acidity/heartburn since the previous visit and repeat the GERD-Q Questionnaire.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 30, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients of both sexes over 18 years of age - Patients with gastroesophageal reflux disease and heartburn (more than 3 weekly episodes of heartburn for at least 4 consecutive weeks) not related to medication intake - Patients not on proton pump blockers or H2-receptor antagonists - Patients able to understand the study implications and who sign the informed consent. Exclusion Criteria: - Pregnant or nursing women - Patients who are currently using or have used other medications or antacid products for the treatment of reflux and hyperacidity symptoms within 7 days prior to enrolment in this study. - Patients treated with antihypertensive drugs, calcium channel blockers or non-steroidal anti-inflammatory drugs (NSAIDs) - Patients with hypercalcaemia, hypertension, renal failure or other conditions in which the use of the components of the investigational product is not recommended. - Patients with serious diseases that, in the physician's opinion, could interfere with the results of the study or prevent their participation in it.

Study Design


Intervention

Device:
Antacid
The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
Other:
Control
The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.

Locations

Country Name City State
Spain Oriol Armengol Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Uriach Consumer Healthcare

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intensity of acidity/heartburn Change in intensity of acidity/heartburn before and after taking the treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable) At the beginning and at the end of treatment, an average of 7±1 days in patients
Primary Time from treatment intake to resolution or maximum decrease in acidity/heartburn Change in time from treatment intake to resolution or maximum decrease in acidity/heartburn as assessed by the patient using a 3-point Likert scale (<1 minute, 1-5 minutes, >5 minutes) At the beginning and at the end of treatment, an average of 7±1 days in patients
Primary Time elapsed between product intake and intragastric pH > 4 Change in minutes of the time elapsed between product intake and intragastric pH > 4 Baseline visit
Primary Time with intragastric pH > 4 for 20 minutes before and after product intake Total time in minutes of the time in intragastric pH > 4 for 20 minutes before and after product intake Baseline visit
Secondary Demographic data Sex, ethnicity and age data of patients Baseline visit
Secondary Time of tablet duration in the mouth before complete dissolution Change in time of tablet duration in the mouth before complete dissolution, assessed using a 4-point Likert scale (< 1 minute, 1-3 minutes, 3-5 min, >5 minutes) At the beginning and at the end of treatment, an average of 7±1 days in patients
Secondary Number of daytime and nightime episodes of acidity/heartburn Change in number of daytime and nightime episodes of acidity/heartburn (information recorded in the Patient Diary) An average of 7±1 days in patients
Secondary Intensity of reflux before and after treatment Change in intensity of reflux before and after treatment, assessed by the patient using a visual analogue scale (VAS from 0=none to 10=maximum imaginable) At the beginning and at the end of treatment, an average of 7±1 days in patients
Secondary Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score Change in Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score. Between 0 and 8 in symptoms questions the score don't mean GERD, more than 8 mean GERD or severe GERD if in impact questions the score is more than 2. At the beginning and at the end of treatment, an average of 7±1 days in patients
Secondary Number of Participants With Adverse Events Number of Participants With Adverse Events as a Measure of Safety and Tolerability From the beginning to the end of treatment, an average of 7±1 days in patients
Secondary Degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product Assessment of degree of physician and patient satisfaction with the efficacy, rapidity of action and tolerability of the product using 5-point Likert scales (0=very dissatisfied, 1=dissatisfied, 2=indifferent, 3=satisfied, 4=very satisfied). Through study completion, an average of 6 months
Secondary Mean intragastric pH Change in mean intragastric pH for 20 minutes before and after product intake Baseline visit
Secondary Number of episodes of GER (intraoesophageal pH < 4) Change in the number of episodes of GER (intraoesophageal pH < 4). Evaluation 20 minutes before and after taking the product Baseline visit
Secondary Time with oesophageal pH < 4 Change in the time with oesophageal pH < 4. Evaluation 20 minutes before and after taking the product Baseline visit
Secondary Longest reflux episode (oesophageal pH <4) Change in the time of longest reflux episode (oesophageal pH <4). Evaluation 20 minutes before and after taking the product Baseline visit
See also
  Status Clinical Trial Phase
Recruiting NCT05320796 - The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass Phase 4
Withdrawn NCT05016076 - Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial N/A
Recruiting NCT05500196 - Impact of Gastric Length of Myotomy During POEM on Gastroesophageal Reflux
Not yet recruiting NCT04105894 - Gastric Reflux and Sinonasal Symptoms